购物车
- 全部删除
- 您的购物车当前为空
CDK8-IN-12 是一种具有选择性、有效性和口服活性的 CDK8 抑制剂(Ki : 14 nM),是一种抗癌剂。CDK8-IN-12 对 GSK-3α、GSK-3β、PCK-θ 具有抑制作用,Ki 分别为 13 nM、4 nM、109 nM。CDK8-IN-12对 MV4-11 细胞显示出抗增殖活性。
为众多的药物研发团队赋能,
让新药发现更简单!
CDK8-IN-12 是一种具有选择性、有效性和口服活性的 CDK8 抑制剂(Ki : 14 nM),是一种抗癌剂。CDK8-IN-12 对 GSK-3α、GSK-3β、PCK-θ 具有抑制作用,Ki 分别为 13 nM、4 nM、109 nM。CDK8-IN-12对 MV4-11 细胞显示出抗增殖活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 519 | 现货 | |
5 mg | ¥ 1,190 | 现货 | |
10 mg | ¥ 1,790 | 现货 | |
25 mg | ¥ 2,970 | 现货 | |
50 mg | ¥ 4,470 | 现货 | |
100 mg | ¥ 6,280 | 现货 | |
200 mg | ¥ 8,470 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,270 | 现货 |
产品描述 | CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showed anti-proliferative activity against MV4-11 cells. |
靶点活性 | CDK8:14 nM(Ki), GSK-3α:13 nM(ki), PCKθ:109 nM(ki), MV-4-11 cells:0.36 μM(GI50), GSK-3β:4 nM(ki) |
体外活性 | CDK8-IN-12 (0.36, 0.72 μM ; 2 h) significantly reduced the phosphorylation of STAT1 serine 727.[1] |
体内活性 | CDK8-IN-12 (intravenous administration ; 5 mg/kg in rats ; 2 mg/kg in mice) had a T1/2 of 0.9 h and 0.34 h in rats and mice, respectively.[1] |
分子量 | 381.86 |
分子式 | C21H20ClN3O2 |
CAS No. | 2613307-67-6 |
Smiles | O=C1C2(CCN(CC2)C=3C(=CN=CC3Cl)C4=CC=5C(O4)=CC=CC5)CCN1 |
密度 | 1.39 g/cm3 at 20℃ (Predicted) |
存储 | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 27.5 mg/mL (72.02 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容